drugset / Trial / NCT03484585
Rogaratinib (BAY1163877) Human Mass Balance Study
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 200 mg dose of \[14C\]rogaratinib given as a solution. For further clinical development, human mass balance data are required to elucidate the absorption, distribution, metabolism, and excretion (ADME) of rogaratinib.
Timeline
- Start
- 2018-04-06
- Primary completion
- 2018-05-25
- Completion
- 2018-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rogaratinib | Small molecule | 200 mg | Oral |
Indications
No indication recorded.